# BioCorRx Inc.

BioCorRx Inc. is an other.

## Overview

- **Organization type:** other
- **Assets under management:** Undisclosed

## Regulatory record

- **Reports private funds:** No

## About

BioCorRx Inc. is a development-stage biopharmaceutical entity focused on treating addiction and substance use disorders. The company’s lead candidate, BICX104, is an implantable, once-monthly naltrexone formulation designed to improve compliance in patients with opioid or alcohol dependence (per SEC filings, 2023). It also markets UnCraveRX, a weight-loss supplement, but the core value driver is the addiction pipeline. Strategy centers on advancing BICX104 through Phase 1 clinical trials, with prior work completed in Spain and planned expansion into US-based studies. BioCorRx does not maintain a disclosed asset-class mix, deployment pace, or a roster of external portfolio companies. The firm operates from a single location, with no publicly known fund structures or co-investment vehicles. Team size is minimal, comprising a handful of named executives — CEO Lourdes Felix, CFO Ajay Grover, and Chief Medical Officer Dr. Steven McCarus — per SEC filings. No philanthropic or operating-company adjacencies are publicly recorded. The most recent operational event is the filing of a patent for BICX104 in April 2024 (per USPTO record). A structural differentiator is the firm’s reliance on a special-purpose vehicle, a 2017 licensing agreement with the University of Texas Health Science Center, which provided the naltrexone implant technology (per SEC filings). This single-source innovation model is rare among family offices and distinguishes BioCorRx as a shallow, asset-owning entity rather than a diversified investment office.

## Questions

### How does BioCorRx source its technology?

BioCorRx licensed its core naltrexone implant technology from the University of Texas Health Science Center in 2017 (per SEC filings). This single-source arrangement limits its pipeline breadth but provides a patented delivery mechanism for addiction treatment.

### What investment stages does BioCorRx target?

BioCorRx operates as a development-stage firm, not an investor. It does not target investment stages, make direct deals, or participate in co-investments. It is a corporate entity advancing a single product through clinical trials.

### What regulatory environment affects BioCorRx?

BioCorRx must comply with FDA requirements for drug approval. Its BICX104 implant received Investigational New Drug clearance in the US in 2022 (per SEC filings), allowing Phase 1 trials.

## Related profiles

- [BTC Digital Ltd.](https://altss.com/profile/btc-digital-ltd)
- [SU Group Holdings Ltd](https://altss.com/profile/su-group-holdings-ltd)

---

Updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/biocorrx-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology